Compare REPX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | REPX | ANL |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 963.9M | 998.8M |
| IPO Year | 2003 | 2022 |
| Metric | REPX | ANL |
|---|---|---|
| Price | $45.48 | $15.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $46.00 | $29.50 |
| AVG Volume (30 Days) | ★ 252.7K | 181.7K |
| Earning Date | 11-04-2026 | 08-14-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | ★ 78.17 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $3,038,000.00 | N/A |
| Revenue This Year | $52.25 | $243.83 |
| Revenue Next Year | $6.87 | N/A |
| P/E Ratio | $55.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.08 | $0.88 |
| 52 Week High | $45.31 | $17.25 |
| Indicator | REPX | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 69.75 | 57.29 |
| Support Level | $32.27 | $14.70 |
| Resistance Level | N/A | $17.10 |
| Average True Range (ATR) | 1.28 | 1.18 |
| MACD | 0.25 | -0.10 |
| Stochastic Oscillator | 94.00 | 70.03 |
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations include: The Permian Basin is an oil and natural gas producing area located in West Texas.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.